Marcus Lefebure

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Arnon P. Kater, Jenny Wu, Thomas J. Kipps et al. · Journal of Clinical Oncology · 2020 · 209 citations · Full text

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

Marta Chesi, Geoffrey M. Matthews, Victoria M. Garbitt et al. · Blood · 2012 · 207 citations

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · Blood · 2022 · 142 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +14

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

Simon J. Hogg, Andrea Newbold, Stephin J. Vervoort et al. · Molecular Cancer Therapeutics · 2016 · 72 citations · Full text

Aggressive B-cell Lymphoma, Apoptosis, Immunology +19

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Arnon P. Kater, Thomas J. Kipps, Barbara Eichhorst et al. · Blood · 2020 · 57 citations